Antibody

189개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved189 programs
AntibodyLimited DatastaleBenaroya Research InstitutePhase 2

Panitumumab or Cetuximab (Anti-EGFR, Anti-EGFR (Panitumumab or Cetuximab))

Colorectal Cancer; Cholangiocarcinoma · EGFR

#EGFR#Antibody#Phase2#monoclonal-antibody#ColorectalCancer+2
Trials 1Status Active
AntibodyLimited DatastaleGustave Roussy, Cancer Campus, …Phase 2

atezolizumab (Tecentriq, Anti-PD-L1 antibody atezolizumab)

Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma ) · PD-L1

#PD-L1#Antibody#Phase2#monoclonal-antibody#PatientsWithMetastaticTumoursCol+3
Trials 1Status Active
AntibodyLimited DatastaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Platinum-SensitiveLungSmallCellC+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

adjuvant (Atezolizumab, Atezolizumab (adjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

neoadjuvant (Atezolizumab, Atezolizumab (neoadjuvant))

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#MetastaticGastricCancer+1
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab combined with bevacizumab combined with β- alanine)

Hepatocellular Carcinoma · Hepatocellular Carcinoma

#HepatocellularCarcinoma#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Recruiting
AntibodyLimited DatastaleYuan YuanPhase 2

Balstilmab (Balstilmab)

Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Triple-Negative Breast Carcinoma · Anatomic Stage IV Breast Cancer AJCC v8

#AnatomicStageIVBreastCancerAJCCv#Antibody#Phase2#monoclonal-antibody#MetastaticTriple-NegativeBreastC+1
Trials 1Status Recruiting
AntibodyLimited DatastaleBayerPhase 1

BAY1905254 (Bapotulimab, Bapotulimab (BAY1905254))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleMerckPhase 1

pembrolizumab (Keytruda, BAY1905254, Bapotulimab, Bapotulimab (BAY1905254) + Pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#monoclonal-antibody#HeadandNeckSquamousCellCarcinoma+1
Trials 1Status Active
AntibodyLimited DatastaleSun Yat-sen UniversityPhase 2

cetuximab (C225, C225 (cetuximab))

Nasopharyngeal Carcinoma · Nasopharyngeal Carcinoma

#NasopharyngealCarcinoma#Antibody#Phase2#monoclonal-antibody#Sun
Trials 1Status Active
AntibodyLimited DatastaleTaizhou Mabtech Pharmaceutical …Phase 1

CMAB819 (CMAB819)

Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma of the Head and

#SquamousCellCarcinomaoftheHeadan#Antibody#Phase1#monoclonal-antibody#Taizhou
Trials 1Status Discontinued
AntibodyLimited DatastaleShen FengPhase 2

Cadonilimab+Gem/Cis (Cadonilimab+Gem/Cis)

Intrahepatic Cholangiocarcinoma · Intrahepatic Cholangiocarcinoma

#IntrahepaticCholangiocarcinoma#Antibody#Phase2#monoclonal-antibody#Shen
Trials 1Status Active
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Cetuximab (Camrelizumab and Cetuximab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 3

Camrelizumab and Chemotherapy (Camrelizumab and Chemotherapy)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#monoclonal-antibody#Jiangsu
Trials 1Status Recruiting
AntibodyLimited DatastaleJiangsu HengruiPhase 2

Camrelizumab+cetuximab+chemotherapy (Camrelizumab+cetuximab+chemotherapy)

Squamous Cell Carcinoma of Head and Neck · Squamous Cell Carcinoma of Head and Neck

#SquamousCellCarcinomaofHeadandNe#Antibody#Phase2#monoclonal-antibody#Jiangsu
Trials 1Status Active
AntibodyLimited DatastaleEli LillyPhase 2

Dalpiciclib+cetuximab (Dalpiciclib+cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Active
AntibodyLimited DatastaleShanghai Ninth People's Hospita…Phase 2

Dalpicilib combined with cetuximab (Dalpicilib combined with cetuximab)

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma · Recurrent/Metastatic Head and Neck Squam

#RecurrentMetastaticHeadandNeckSq#Antibody#Phase2#monoclonal-antibody#Recurrent+2
Trials 1Status Recruiting
AntibodyLimited DatastaleTesaro, Inc.Phase 3

TSR-042 (Dostarlimab, Dostarlimab (TSR-042))

Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma · Ovarian Neoplasms

#OvarianNeoplasms#Antibody#Phase3#monoclonal-antibody#Ovarian+2
Trials 1Status Recruiting
AntibodyLimited DatastaleCelgenePhase 2

Duravalumab (Duravalumab)

Carcinoma, Non-Small-Cell Lung · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#monoclonal-antibody#Carcinoma+2
Trials 1Status Active

5 / 10 pages

← PreviousNext →